Supplementary Quarterly Financial Data (Unaudited)

12 Months Ended

Jun. 30, 2019

17.	SUPPLEMENTARY QUARTERLY FINANCIAL DATA (UNAUDITED)

Unaudited financial data by quarter for fiscal 2019.

In millions, except per share amounts	Quarters Ended
	Jun 30,			Mar 31,			Dec 31,			Sep 30,
Consolidated Statement of Operations Data:	2019			2019			2018			2018
Molecular diagnostic testing	$	196.9		$	200.5		$	203.0		$	189.0
Pharmaceutical and clinical services		18.5			16.1			13.8			13.3
Total Revenue		215.4			216.6			216.8			202.3
Costs and expenses:
Cost of molecular diagnostic testing		41.6			40.3			44.0			42.3
Cost of pharmaceutical and clinical services		9.0			8.3			8.1			7.4
Research and development expense		20.9			21.5			22.4			21.1
Change in the fair value of contingent consideration		(0.3	)		—			1.0			0.4
Selling, general and administrative expense		149.8			140.6			135.2			129.9
Total costs and expenses		221.0			210.7			210.7			201.1
Operating income		(5.6	)		5.9			6.1			1.2
Other income (expense):
Interest income		0.9			0.7			0.9			0.7
Interest expense		(3.2	)		(3.2	)		(3.4	)		(2.2	)
Other		0.2			(0.1	)		—			1.1
Total other income (expense)		(2.1	)		(2.6	)		(2.5	)		(0.4	)
Income before income taxes		(7.7	)		3.3			3.6			0.8
Income tax provision		(3.4	)		(3.6	)		1.0			1.6
Net income		(4.3	)		6.9			2.6			(0.8	)
Net loss attributable to non-controlling interest		(0.1	)		—			—			(0.1	)
Net income attributable to Myriad Genetics, Inc. stockholders	$	(4.2	)	$	6.9		$	2.6		$	(0.7	)
Earnings per share:
Basic	$	(0.06	)	$	0.09		$	0.04		$	(0.01	)
Diluted	$	(0.06	)	$	0.09		$	0.03		$	(0.01	)
Weighted average shares outstanding:
Basic		73.4			73.3			74.2			73.0
Diluted		74.8			74.9			76.5			73.0

In millions, except per share amounts	Quarters Ended
	Jun 30,			Mar 31,			Dec 31,			Sep 30,
Consolidated Statement of Operations Data:	2018 (a)			2018 (a)			2017 (a)			2017 (a)
Molecular diagnostic testing	$	180.6		$	169.3		$	173.1		$	167.4
Pharmaceutical and clinical services		13.3			13.8			14.8			11.4
Total Revenue		193.9			183.1			187.9			178.8
Costs and expenses:
Cost of molecular diagnostic testing		38.0			36.8			37.7			36.2
Cost of pharmaceutical and clinical services		7.7			7.3			6.7			6.8
Research and development expense		17.7			18.5			16.8			17.8
Change in contingent consideration		0.2			(1.2	)		13.0			(73.2	)
Selling, general and administrative expense		112.5			107.9			107.4			107.2
Total costs and expenses		176.1			169.3			181.6			94.8
Operating income		17.8			13.8			6.3			84.0
Other income (expense):
Interest income		0.5			0.5			0.4			0.4
Interest Expense		(1.1	)		(0.5	)		(0.7	)		(0.9	)
Other		0.8			(0.5	)		(0.4	)		(0.3	)
Total other income (expense)		0.2			(0.5	)		(0.7	)		(0.8	)
Income before income taxes		18.0			13.3			5.6			83.2
Income tax provision		3.5			4.3			(25.3	)		4.5
Net income		14.5			9.0			30.9			78.7
Net loss attributable to non-controlling interest		—			(0.1	)		—			(0.1	)
Net income attributable to Myriad Genetics, Inc. stockholders	$	14.5		$	9.1		$	30.9		$	78.8
Earnings per share:
Basic	$	0.21		$	0.13		$	0.45		$	1.15
Diluted	$	0.20		$	0.13		$	0.43		$	1.12
Weighted average shares outstanding:
Basic		70.1			69.8			69.3			68.6
Diluted		72.9			72.4			71.9			70.4

(a)	Amounts adjusted due to the adoption of Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606). See Note 1 to the financial statements of this report for additional information.